JP2016540022A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540022A5
JP2016540022A5 JP2016539166A JP2016539166A JP2016540022A5 JP 2016540022 A5 JP2016540022 A5 JP 2016540022A5 JP 2016539166 A JP2016539166 A JP 2016539166A JP 2016539166 A JP2016539166 A JP 2016539166A JP 2016540022 A5 JP2016540022 A5 JP 2016540022A5
Authority
JP
Japan
Prior art keywords
carbonyl
amino
phenoxy
indole
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016539166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540022A (ja
JP6219523B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077124 external-priority patent/WO2015086642A1/en
Publication of JP2016540022A publication Critical patent/JP2016540022A/ja
Publication of JP2016540022A5 publication Critical patent/JP2016540022A5/ja
Application granted granted Critical
Publication of JP6219523B2 publication Critical patent/JP6219523B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016539166A 2013-12-13 2014-12-10 ブルトンチロシンキナーゼの阻害剤 Expired - Fee Related JP6219523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915582P 2013-12-13 2013-12-13
US61/915,582 2013-12-13
PCT/EP2014/077124 WO2015086642A1 (en) 2013-12-13 2014-12-10 Inhibitors of bruton's tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2016540022A JP2016540022A (ja) 2016-12-22
JP2016540022A5 true JP2016540022A5 (enExample) 2017-09-28
JP6219523B2 JP6219523B2 (ja) 2017-10-25

Family

ID=52016584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016539166A Expired - Fee Related JP6219523B2 (ja) 2013-12-13 2014-12-10 ブルトンチロシンキナーゼの阻害剤

Country Status (10)

Country Link
US (1) US9556150B2 (enExample)
EP (1) EP3080099B1 (enExample)
JP (1) JP6219523B2 (enExample)
KR (1) KR101768402B1 (enExample)
CN (1) CN105793252B (enExample)
CA (1) CA2931189C (enExample)
MX (1) MX374758B (enExample)
RU (1) RU2648236C2 (enExample)
TW (1) TW201534600A (enExample)
WO (1) WO2015086642A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2653504C2 (ru) 2013-12-13 2018-05-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
ES2756175T3 (es) 2013-12-27 2020-04-27 Chugai Pharmaceutical Co Ltd Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos
EP3312172B1 (en) 2015-06-17 2020-05-06 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives useful as src kinase inhibitors
RU2018103913A (ru) 2015-07-02 2019-08-02 Асерта Фарма Б.В. Твердые формы и композиции (s)-4-(8-амино-3-(1-(бут-2- иноил)пирролидин-2-ил)имидазо[1,5-a]пиразин-1-ил)-n-(пиридин-2-ил)бензамида
US10871459B2 (en) 2017-02-17 2020-12-22 The Regents Of The University Of California Systems and methods for making assignments in isotope-labelled proteins using nuclear magnetic resonance data
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
FR2772763B1 (fr) 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US20030236288A1 (en) 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
EP1638923A2 (en) 2003-06-24 2006-03-29 Uniroyal Chemical Company, Inc. Fungicidal phenoxyphenylhydrazine derivatives
NZ549396A (en) 2004-03-26 2010-04-30 Hoffmann La Roche Tetrahydrocarbazoles and derivatives
EA012211B1 (ru) 2005-01-07 2009-08-28 Пфайзер Продактс Инк. Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
EP2298770A1 (en) 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
WO2007062318A2 (en) 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
EP2114941B1 (en) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
WO2008122614A1 (en) 2007-04-06 2008-10-16 Novartis Ag 2, 6-naphthyridine derivatives as protein kinase modulators
WO2008141119A2 (en) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
EP2297142B1 (en) * 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
AR084370A1 (es) * 2009-08-07 2013-05-15 Chugai Pharmaceutical Co Ltd Derivados de aminopirazol
WO2012078859A2 (en) 2010-12-09 2012-06-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Protein kinase d inhibitors
JP5620417B2 (ja) 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬

Similar Documents

Publication Publication Date Title
JP2014531449A5 (enExample)
US9833455B2 (en) Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
TWI455939B (zh) cMET抑制劑
JP2015527401A5 (enExample)
JP2010533160A5 (enExample)
JP2016510035A5 (enExample)
JP2017504635A5 (enExample)
JP2024540445A5 (enExample)
JP2007519694A5 (enExample)
HRP20210454T1 (hr) 3-supstituirani 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-dion spojevi za liječenje i profilaksu virusne infekcije
IL273000B2 (en) Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)
JP2010513283A (ja) 新規なオキサジアゾール化合物
JP2013518129A5 (enExample)
JP2012522847A5 (enExample)
RU2009142431A (ru) Производные триазолопиридинкарбоксамидов и триазолопиримидинкарбоксамидов, их получение и их применение в терапии
NZ601077A (en) Use of an adrenal hormone-modifying agent
JP2013543896A5 (enExample)
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
JP2015519401A5 (enExample)
US8563562B2 (en) Compounds having antiviral properties
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
RU2009142434A (ru) Производные триазолопиридин-карбоксамидов и триазолопиримидин-карбоксамидов, их получение и их применение в терапии
JP2016532715A5 (enExample)
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
JP2019504901A5 (enExample)